Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Blood (2024) 144 (Supplement 1): 225.

https://doi.org/10.1182/blood-2024-204503

Published: 2024

Journal Articles

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial

Natalia Tovar, Valentin Ortiz-Maldonado, Nuria Martinez-Cibrian, Sergi Betriu, Daniel Esteban, Ana Triguero, Nadia Verbruggen, Maike Spoon, Marte C. Liefaard, Margot Pont, Anna D.D. van Muyden

Blood (2023) 142 (Supplement 1): 2112.

https://doi.org/10.1182/blood-2023-189321

Published: 2023

Journal Articles

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 4230.

https://doi.org/10.1182/blood-2023-185484

Published: 2023

Journal Articles

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Blood (2023) 142 (Supplement 1): 1858.

https://doi.org/10.1182/blood-2023-186777

Published: 2023

Journal Articles

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Blood (2023) 142 (Supplement 1): 3231.

https://doi.org/10.1182/blood-2023-173311

Published: 2023

Journal Articles

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Blood (2023) 142 (Supplement 1): 3550.

https://doi.org/10.1182/blood-2023-179852

Published: 2023

Journal Articles

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Blood (2023) 142 (Supplement 1): 7018.

https://doi.org/10.1182/blood-2023-181076

Published: 2023

Journal Articles

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Josep-Maria Ribera, Olga Garcia, Jordi Ribera, Pau Montesinos, Isabel Cano, Pilar Martínez, Jordi Esteve, Daniel Esteban, María García-Fortes, Natalia Alonso, José González-Campos, Arancha Bermúdez, Anna Torrent, Eulàlia Genescà, Santiago Mercadal, Joaquín Martínez-López, Ramon Garcia-Sanz

Blood (2021) 138 (Supplement 1): 1230.

https://doi.org/10.1182/blood-2021-148310

Published: 2021

Journal Articles

Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1× 10 9 /L Should be Classified As CMML

Sandra Castaño-Díez, Monica Lopez-Guerra, PhD, Daniel Esteban, Francesca Guijarro, MD, Alex Bataller Torralba, MD, Paola Charry, MD, Carlos Castillo, MD, Carlos Jiménez-Vicente, MD, Colomer Dolors, María Rozman, MD, Jordi Esteve, Marina Diaz-Beyá, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-142819

Published: 2020

Journal Articles

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Sandra Castaño-Díez, Monica Lopez-Guerra, PhD, Francesca Guijarro, MD, Alex Bataller Torralba, MD, Daniel Esteban, Carlos Castillo, MD, Carlos Jiménez-Vicente, MD, Paola Charry, MD, Colomer Dolors, María Rozman, MD, Jordi Esteve, Marina Diaz-Beyá, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-142740

Published: 2020

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Josep-Maria Ribera, Olga García, Pau Montesinos, MD PhD, Pilar Martinez, MD, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, MD, Anna Torrent, Joaquin Martinez-Lopez, MD, Santiago Mercadal, MD, Ramon Garcia-Sanz

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137489

Published: 2020

Journal Articles

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Josep-Maria Ribera, MD PhD, Olga García, Pilar Martinez, MD, Pau Montesinos Fernandez, MD PhD, Blanca Boluda, Jordi Esteve, Daniel Esteban, María José Moreno, MD, Natalia Alonso, José González-Campos, MD, Arancha Bermúdez, Susana Vives, MD, Mar Tormo, MD PhD, Jesús María Hernández-Rivas, MD PhD, Joaquin Martinez-Lopez, MD PhD, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 3874.

https://doi.org/10.1182/blood-2019-125558

Published: 2019

Journal Articles

Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma

Meritxell Nomdedeu, MD, PhD, Marta Pratcorona, MD, Marina Díaz-Beyá, MD, Xavier Calvo, MD, Mari Carmen Lara-Castillo, PhD, Daniel Esteban, MD, Maria Rozman, MD, PhD, Dolors Costa, PhD, Jordi Esteve, MD, PhD, Ruth M. Risueño, PhD

Blood (2013) 122 (21): 1422.

https://doi.org/10.1182/blood.V122.21.1422.1422

Published: 2013

Journal Articles

Recurrent Mutations Of NOTCH Genes In Follicular Lymphoma

Kennosuke Karube, Daniel Martinez, Cristina Royo, PhD, Paola Castillo, Alexandra Valera, Andreas Rosenwald, MD, German Ott, MD, Daniel Esteban, MD, Eva Gine, MD, PhD, Armando Lopez-Guillermo, MD, PhD, Elias Campo

Blood (2013) 122 (21): 4253.

https://doi.org/10.1182/blood.V122.21.4253.4253

Published: 2013

NARROW

Prognostic Value of the Measurable Residual Disease (MRD) in AML Treatment with Venetoclax in Combination with Hypomethylating Agents: Validation of the ELN 2021 MRD Recommendations

Seven-Day Vein-to-Vein Point-of-Care Manufactured CD19 CAR T Cells (GLPG5201) in Relapsed/Refractory CLL/SLL Including Richter's Transformation: Results from the Phase 1 Euplagia-1 Trial

Validation of ELN 2022 Risk Classification in Patients Diagnosed with AML Undergoing Allogeneic Hematopoietic Cell Transplantation

Venetoclax and Azacytidine Treatment for High Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia As a Bridge Therapy to Transplant. a GESMD Study

Chronic Myelomonocytic Leukemia (CMML) with AML Typical Mutations ( NPM1, FLT3 or CEBPA ) Identify a High-Risk CMML Group Independent of Molecular-Cpss

Allogeneic Hematopoietic Cell Transplantation with Sequential-Based Conditioning in Refractory / Relapsed Acute Myeloid Leukemia: Experience from a Single Institution

Evaluation of the Use of Post-Transplant Cyclophosphamide in Patients Diagnosed of Myelodysplastic Syndrome Who Undergo Allogenic Hematopoietic Cell Transplantation

Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial

Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1× 10 9 /L Should be Classified As CMML

Emergence of NPM1 Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia with NPM1 Mutation: Proposed Mechanisms of Clonal Evolution

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment

Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial

Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma

Recurrent Mutations Of NOTCH Genes In Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only